Literature DB >> 1516034

Expression of epidermal growth factor receptor and transforming growth factor alpha in human larynx carcinoma.

E Di Marco1, E Albanese, S Benso, F Beatrice, R Cancedda, S Toma.   

Abstract

Altered expression of growth factors and growth factor receptors is frequently described in human tumors and human tumor cell lines. This further supports the hypothesis that oncogenesis is due to the subversion of mitogen-responsive pathways. The aim of this study was to investigate the expression of epidermal growth factor receptor (EGFR) and transforming growth factor alpha (TGF alpha) in 13 larynx carcinomas and 2 carcinomas of the oral cavity. We found receptor overexpression in 7 out of 15 tumors at mRNA and/or protein level but low expression in the majority of the normal adjacent tissues. TGF alpha was expressed only in 1 case, but no tyrosine kinase activity of the receptor was detected by antiphosphotyrosine antibody.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516034     DOI: 10.1016/0304-3835(92)90231-j

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

Review 2.  Biological staging of head and neck cancer and its role in developing effective treatment strategies.

Authors:  W M Lydiatt; S P Schantz
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

3.  Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic Applications.

Authors:  Francesca Malerba; Francesca Paoletti; Bruno Bruni Ercole; Serena Materazzi; Romina Nassini; Elisabetta Coppi; Riccardo Patacchini; Simona Capsoni; Doriano Lamba; Antonino Cattaneo
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.